Verita Neuro has entered into an exclusive distribution partnership with NASDAQ-listed Lifeward Ltd. (NASDAQ: LFWD) to integrate the FDA-cleared ReWalk® Personal Robotic Exoskeleton into its world-leading spinal cord injury rehabilitation programmes.

The agreement makes Verita Neuro the exclusive distributor of ReWalk® in Mexico, Thailand and the United Arab Emirates, where the device will be deployed alongside Verita Neuro’s Epidural Stimulation, LamiSpine and intensive personalised rehabilitation protocols. The partnership represents a new global delivery model for ReWalk® – the first integration of the device with in-patient training and rehabilitation worldwide.

“As the global pioneer in neurological restoration, Verita Neuro redefined Epidural Stimulation reconnecting brain-body pathways to regain voluntary movement,” said Julian Andriesz, CEO of Verita Neuro and Verita Healthcare. “Through Lifeward’s ReWalk exoskeleton in our in-patient programme, we’re achieving another world first — seamless multimodal enablement.”

Read more at: https://veritaneuro.com/news/verita-neuro-partners-with-lifeward-to-introduce-rewalk-personal-robotic-exoskeleton/